Status:
COMPLETED
An Efficacy and Safety Study of Ustekinumab (CNTO 1275) in Participants With Plaque Psoriasis
Lead Sponsor:
Janssen Pharmaceutical K.K.
Conditions:
Psoriasis
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of ustekinumab (CNTO 1275) compared with placebo in participants with moderate to severe plaque type psoriasis.
Detailed Description
This is a multicenter (involving more than 1 study center), randomized (study medication assigned by chance), double-blind (neither the invesitigator nor the participant knows the identity of the stud...
Eligibility Criteria
Inclusion
- Participants diagnosed with psoriasis (psoriasis vulgaris and psoriatic arthritis) at least 6 months before registration
- Participants with plaque type psoriasis covering at least 10 percent of total body surface area at the time of informed consent and at registration
- Participants with a PASI score of greater than or equal to 12 at the time of informed consent and at registration
- Female participants of childbearing potential or males, whose partner can be pregnant, must agree that he/she will continuously take an appropriate contraceptive measure for 1 year from the day of informed consent to termination of the final investigational treatment; in the case of childbearing potential females, pregnancy test at screening must be negative
- Participants must agree not to receive Bacillus Calmette-Guérin (BCG) vaccination and live vaccine inoculation for 1 year after final treatment with the investigational product
Exclusion
- Participants with guttate psoriasis, erythrodermic psoriasis, or pustular psoriasis
- Participants with a medical history of tuberculosis infection or suspected tuberculosis infection
- Participants with present or past history of chronic or recurrent infection (e.g., chronic or recurrent urinary tract infection or respiratory infection)
- Participants with a current serious infection (e.g., sepsis, hepatitis, pneumonia, or pyelonephritis) or those who experienced a serious infection within the 2 month period before registration and including participants who received intravenous administration of antibiotics or antiviral agents within the 2 month period before registration
- Participants with a current or past history of malignant tumors (except for basal cell carcinoma, intraepidermal squamous cell carcinoma in the skin and uterine cervical squamous cell carcinoma, whose treatment was completed and no sign suggesting a recurrence has been observed, and squamous cell carcinoma in the skin whose treatment was completed and no sign suggesting a recurrence has been observed in the past 5 years)
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
158 Patients enrolled
Trial Details
Trial ID
NCT00723528
Start Date
March 1 2008
End Date
March 1 2010
Last Update
May 20 2014
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
Asahikawa, Japan
2
Chitose, Japan
3
Chūō, Japan
4
Fukuoka, Japan